IOSP FINANCIAL STATEMENTS

Innospec Inc — balance sheet, income statement and cash flow trends

IOSPInnospec Inc

🇺🇸 USA · NASDAQ · Basic Materials · Specialty Chemicals

Value it Duel

Income Statement

Quarterly progression — trailing-twelve-month values

RevenueNet Income

Profit Funnel

Q1 2026 · TTM

Percentages are relative to revenue.

Key Figures

YoY change

Revenue1.8 B $+0.2%

Gross Profit490.8 M $-4.2%

Operating Income144.3 M $-15.1%

EBITDA179 M $-16.2%

Net Income114.2 M $+323.0%

Peer Comparison· Specialty Chemicals

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
IOSP	0.2%	27.4%	10.0%	6.4%
SASA	4.0%	7.7%	15.6%	-36.0%
DNL	-16.6%	27.9%	17.8%	4.5%
IMCD	1.2%	17.7%	10.9%	4.5%
MRSHL	-13.7%	46.2%	13.3%	-4.4%
ORI	1.8%	19.2%	17.3%	3.1%
Industry median	1.2%	26.7%	14.7%	3.5%

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
IOSP	0.2%	27.4%	10.0%	6.4%
MTX	2.5%	24.9%	17.3%	7.6%
NGVT	-10.3%	39.3%	1.4%	-10.6%
KWR	6.3%	34.4%	8.8%	0.2%
CC	0.1%	15.1%	2.3%	-7.1%
HWKN	11.2%	22.6%	16.2%	7.5%
Industry median	1.2%	26.7%	14.7%	3.5%

Balance Sheet

Quarterly period-end values

Total AssetsTotal LiabilitiesEquity

Capital Structure

Q1 2026

Equity1.3 B $74%
Current Liabilities334.8 M $18%
Long-term Liabilities132.8 M $7%

Key Figures

YoY change

Total Assets1.8 B $+2.5%

Total Liabilities467.6 M $-8.1%

Total Equity1.3 B $+6.7%

Cash & ST Investments289.1 M $-3.6%

Total Debt50.6 M $+14.0%

Net Debt-238.5 M $—

Peer Comparison· Specialty Chemicals

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
IOSP	2.98	3.8%	-1.33	73.9%
SASA	0.63	83.7%	14.70	48.5%
DNL	1.27	39.7%	2.15	57.8%
IMCD	1.73	83.4%	2.81	44.0%
MRSHL	1.00	58.2%	0.57	26.2%
ORI	1.31	86.9%	1.77	38.5%
Industry median	1.87	63.0%	2.15	46.9%

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
IOSP	2.98	3.8%	-1.33	73.9%
MTX	2.13	55.9%	1.75	49.9%
NGVT	1.42	3,199.7%	67.21	2.4%
KWR	2.45	65.2%	4.31	49.1%
CC	1.82	2,042.3%	29.00	3.0%
HWKN	2.21	49.0%	1.47	53.3%
Industry median	1.87	63.0%	2.15	46.9%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values

Operating Cash FlowCapital ExpendituresFree Cash Flow

Cash Flow Bridge

Q1 2026 · TTM

Key Figures

YoY change

Operating Cash Flow127.6 M $-3.5%

Capital Expenditures50.8 M $+6.3%

Free Cash Flow76.8 M $-9.0%

Dividends Paid-42.4 M $-209.3%

Peer Comparison· Specialty Chemicals

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
IOSP	7.1%	4.3%	2.8%	111.7%
SASA	13.5%	3.8%	10.3%	-37.5%
DNL	9.3%	-0.2%	9.5%	205.3%
IMCD	6.7%	6.5%	0.3%	148.1%
MRSHL	2.4%	0.1%	2.3%	-54.0%
ORI	11.6%	6.2%	5.4%	372.9%
Industry median	9.6%	5.8%	5.0%	111.7%

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
IOSP	7.1%	4.3%	2.8%	111.7%
MTX	10.8%	5.6%	5.3%	142.4%
NGVT	25.1%	20.3%	4.8%	-237.7%
KWR	7.4%	7.4%	1.3%	3,364.4%
CC	5.7%	2.6%	3.1%	-80.8%
HWKN	13.3%	7.9%	5.4%	177.0%
Industry median	9.6%	5.8%	5.0%	111.7%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on IOSP

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.